---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-281817"
form_type: "8-K"
ticker: "KYMR"
cik: "0001815442"
company_name: "Kymera Therapeutics, Inc."
filed_at: "2026-06-25T11:10:11+00:00"
generated_at: "2026-06-25T11:15:24.477166+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Kymera completes enrollment in Phase 2b KT-621 AD trial; topline data accelerated to year-end 2026

## Summary
- Enrollment in BROADEN2 completed nearly six months ahead of schedule; topline data now expected by year-end 2026.
- Phase 3 trials in atopic dermatitis planned to initiate by mid-2027, subject to regulatory discussions.
- BROADEN2 is a randomized, double-blind, placebo-controlled trial in ~200 patients ages 12-75 over 16 weeks.
- KT-621 also in BREADTH Phase 2b asthma trial with data expected in late 2027.

## SEC filing metadata
- accession: 0001193125-26-281817
- form_type: 8-K
- ticker: KYMR
- cik: 0001815442
- company_name: Kymera Therapeutics, Inc.
- filed_at: 2026-06-25T11:10:11+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1815442/000119312526281817/0001193125-26-281817-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1815442/000119312526281817/d62555d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-281817
- JSON: https://secwatch.observer/filing/0001193125-26-281817.json
- Plain text: https://secwatch.observer/filing/0001193125-26-281817.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.